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Abstract
Background: Benin has recently shifted its national antimalarial drug policy from monotherapies
to combinations containing artemisinin derivatives. When this decision was taken, the available
information on alternatives to chloroquine and sulphadoxine-pyrimethamine, the first- and second-
line treatment, was sparse.
Methods: In 2003 – 2005, before the drug policy change, a randomized, open-label, clinical trial
was carried out on the efficacy of chloroquine, and sulphadoxine-pyrimethamine alone or
combined with artesunate, with the aim of providing policy makers with the information needed to
formulate a new antimalarial drug policy. Children between six and 59 months of age, with
uncomplicated malaria and living in the lagoon costal area in southern Benin, were randomly
allocated to one of the three study arms and followed up for 28 days.
Results: Treatment failure (PCR corrected) was significantly lower in the artesunate +
sulphadoxine-pyrimethamine group (4/77, 5.3%) than in chloroquine group(51/71, 71.8%) or the
sulphadoxine-pyrimethamine alone group (30/70, 44.1%) (p < 0.001). Despite high sulphadoxine-
pyrimethamine failure, its combination with artesunate greatly improved treatment efficacy.
Conclusion: In Benin, artesunate + sulphadoxine-pyrimethamine is efficacious and could be used
when the recommended artemisinin-based combinations (artemether-lumefantrine and
amodiaquine-artesunate) are not available. However, because sulphadoxine-pyrimethamine is also
used in pregnant women as intermittent preventive treatment, its combination with artesunate
should not be widely employed in malaria patients as this may compromise the efficacy of
intermittent preventive treatment.
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Background
In Benin, early malaria case management, both at health
facility and community level, is the backbone of the
national malaria control strategy [1]. High chloroquine
(CQ) resistance, the first-line treatment for many years,
has lead to a review of the national antimalarial policy in
2004 [1-3]. Two artemisinin-based combination treat-
ments (ACTs) were recommended for uncomplicated fal-
ciparum malaria, namely artemether-lumefantrine (AL)
and amodiaquine-artesunate (AQ-AS). Unfortunately, the
implementation of the new national antimalarial drug
policy currently meets several obstacles. Despite their
availability in the pharmacies of the economic capital,
Cotonou, and of other major cities, these ACTs are still
not available in the public health facilities, and even less
at community level. Thus, the large majority of the popu-
lation does not have access to this newly recommended
treatment, mainly because of its cost. Consequently,
malaria patients continue to be treated with CQ, despite
its low efficacy.
In Benin, CQ resistance was first reported in 1986 [4-6]
and, in 1998, it was estimated at 23.8% in the south and
21.4% in the north, at day 14 after treatment (A. Massoug-
bodji, personal communication) according to the 1996
WHO guidelines [7]. CQ resistance was higher (35.2%)
when the follow-up was extended to 28 days after treat-
ment [3,8].
Sulphadoxine-pyrimethamine (SP) efficacy was assessed
in 2002 in five different sites with varying intensity of
malaria transmission [3]. It had a patchy distribution with
an overall treatment failure at day 28 of 22.8%, but rang-
ing from 3.3% to 45.9%. However, it should be noted that
none of these estimates was corrected by genotyping and
the true treatment failure, excluding new infections, is
probably lower. SP is currently used for intermittent pre-
ventive treatment (IPT) in pregnant women and there are
plans to use it as IPT in infants [1,9]. No data on alterna-
tive treatments to CQ and SP were available in Benin at
the time when the national drug policy was revised. A ran-
domized clinical trial was carried out on the efficacy of the
first- and second-line treatment, CQ and SP-alone, and SP
associated with artesunate (SP-AS), in children with
uncomplicated malaria living in the lagoon costal area in
southern Benin.
Methods
Study site and population
This is a randomized trial conducted at three adjacent
peri-urban sites: Ladji, Awansori and Toweta, situated in
the coastal lagoon area of Cotonou. Anopheles gambiae and
Anopheles melas are the main malaria vectors [10], and the
annual entomologic inoculation rate (AEIR) has been
estimated at 58 infective bites per person [10,11]. Preva-
lence of malaria infection in children between two and
nine years of age is high and defines this area as hyper-
endemic [12].
The local authorities and the population were informed
about the study and its objectives in 2001. A census was
carried out in 2002–2003. Houses were numbered and
information on the household's residents (name, sex, age,
relationship with the household head) collected. A list of
six to 59 months old children without any obvious
chronic illness, with parents willing to participate to the
study, and unlikely to emigrate outside the study area was
produced. Five hundred and fifty three children (34% of
all children of this age group) were randomly chosen from
this list to be part of the cohort under surveillance. Parents
or legal guardians were asked before inclusion to sign an
informed consent form. Refusal to participate did not
affect access to basic health services. Parents/guardians
were instructed to attend the nearby health facility, where
a physician was always available, whenever their child was
sick. They were also asked to administer to the child only
drugs given or prescribed by the research physician.
Starting from July 2003 up to January 2005, each child
was visited twice a week by the research team. Body tem-
perature was measured routinely during home visits and,
if the child was febrile (body temperature ≥ 37.5°C), a
blood sample for parasitaemia (thick and thin blood
film) and for genotyping at a later stage (filter paper What-
man grade 3) was collected. A similar approach was
applied to children attending health facilities within the
study area. An additional blood sample for PCV was col-
lected in children with a Plasmodium falciparum mono-
infection with a density between 1,000–200,000/μL. Chil-
dren were allocated to one of the study treatment groups,
i.e. CQ, SP or SP-AS if they met no exclusion criteria: PCV
< 25%, severe malaria [13], danger signs (prostration, ina-
bility to drink, recent convulsion, persistent vomiting) or
other concomitant illness or underlying disease. Alloca-
tion to treatment groups was done according to a prede-
fined randomization list and was concealed (sealed
opaque envelopes) until final recruitment of the patient.
Treatment was administered according to the body weight
at the following doses: CQ: 10 mg/kg/day on days 0 and
1, and 5 mg/kg on day 2; SP: 25 mg/kg of sulphadoxine
and 1.25 mg/kg of pyrimethamine as a single dose on day
0; SP as before plus artesunate: 4 mg/kg/day for three
days. Treatment was administered directly by the study
team and patients were observed for one hour. Treatment
was repeated if vomiting occurred: a full dose if within 30
minutes and half dose if between 30 minutes and one
hour. If vomiting persisted, the patient was referred to the
health facility and rescue treatment was given (full course
of quinine, according to Benin National Treatment Guide-
lines [1]). A case-record form was completed for each
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patient documenting all symptoms prior to treatment,
concomitant illness and drug history. Besides the first
three days of treatment (days 0, 1 and 2), children were
seen at scheduled visits at days three, seven, 14, 21 and 28.
In addition, parents/guardians were encouraged to attend
the health facilities whenever the child was sick. At each
visit, the clinical history, signs and symptoms, body tem-
perature were recorded and a blood sample was collected
for parasitaemia and genotyping at a later stage.
Laboratory methods
Thick blood films were stained with Giemsa (10% for 10
minutes). Parasite density was determined on a thick
blood film according to the number of parasites per 200
white blood cells (WBC), and assuming a total WBC
count of 8,000/μl. If gametocytes were seen, the gameto-
cyte count was extended at 1,000 WBC. Microscopy exam-
ination was totally blinded to the patient's identity and
treatment group. PCV, measured by micro-haematocrit
centrifugation, was assessed on days 0, 14 and 28. Geno-
typing, to distinguish between a new infection and a
recrudescence, was done on blood samples collected
before treatment and at the time of any recurrent parasi-
taemia and was performed at the Institute of Tropical
Medicine, Antwerp, Belgium. DNA was extracted as
described elsewhere. Parasite genotyping was done by
nested PCR for variable blocks within the merozoite sur-
face protein 1 and 2 (msp1and msp2) as described previ-
ously [14,15]. A recrudescence was defined by observing
at least one common band for both markers between the
infections before treatment at day 0 and at the time of
recurrent parasitaemia. New infection was defined by
completely different bands between the two infections in
at least one of the two markers.
Outcome measurements
Outcomes were defined according to the standard WHO
classification [16]. Early treatment failure (ETF) was
defined as one of the following: i) danger signs/severe
malaria at day 1, 2 or 3 with parasitaemia; ii) parasite den-
sity at day 2 greater than at day 0; iii) parasitaemia at day
3 with fever (axillary temperature ≥ 37.5°C); iv) parasite
density at day 3 equal or greater than 25% of that at day
0. Late clinical failure (LCF) was defined as danger signs/
severe malaria or parasitaemia with fever occurring
between day 4 and day 28, without having been previ-
ously classified as ETF. Late parasitological failure (LPF)
was defined as parasitaemia without fever between day 4
and day 28 and without previously meeting any of the cri-
teria for ETF or LCF. An adequate clinical and parasitolog-
ical response (ACPR) was defined as the absence of
parasitaemia by day 28 without previously meeting any of
the criteria for ETF, LCF and LPF. The primary outcomes
were day-28 failure rates (uncorrected and PCR cor-
rected). Total treatment failure (TTF) was computed as
ETF+LCF+LPF. After day 14 only infections confirmed by
PCR as recrudescence were considered as treatment fail-
ures. Secondary outcomes included fever, parasite and
gametocyte clearance.
Statistical analysis
Data were analysed in STATA version 8.0 (Stata Corpora-
tion, College Station, Texas, US). Descriptive statistics
were used to summarize baseline values and demography
data.
Analysis of variance (ANOVA) was used for normally dis-
tributed continuous data. Data not normally distributed
were compared by Wilcoxon Rank sum or Kruskal-Wallis
tests. Categorical data were compared by calculating the
chi-square value or by Fisher's exact test. Data were ana-
lysed by Intention-to-Treat (ITT), Per-Protocol (PP) and
Kaplan Meier survival analysis to determine the cure rate
(PCR corrected) at day 28 in each treatment group. In the
ITT analysis, patients lost to follow up were considered as
treatment failures (worst case scenario) and the denomi-
nator was the number of patients initially randomized to
each group. In the PP analysis, patients lost to follow-up
and those excluded after enrolment were excluded from
the analysis; only patients with a complete follow-up were
included in the denominator. Cure rates, fever and para-
site clearance were compared using logistic regression
models. Odds ratio and 95% CI were estimated from
these models. In the Kaplan Meier survival analysis, each
patient contributed to the analysis for the time s/he was
followed up. Data were censored for patients who did not
complete follow up and for new P. falciparum infection
when estimating outcomes corrected by PCR. In the sur-
vival analysis, cure rates were described by Kaplan Meier
estimates and compared between groups with a log-rank
test. Pair-wise comparisons of treatment efficacy at day 28
were made with a Cox proportional hazards model.
Gametocyte carriage rates were estimated as proportion of
patients with gametocytaemia and person-gametocyte-
weeks (PGW) were calculated to measure gametocyte car-
riage and transmission potential. The PGW were calcu-
lated as the number of weeks in which blood slides were
positive for gametocytes during the two first weeks of fol-
low-up after treatment divided by the number of all fol-
low-up weeks and expressed per 1,000 person-weeks. P <
.05 was considered statistically significant.
Ethical approval
The study was approved by the Minister of Health of
Benin, the Ethical Committee of the Faculté des Sciences
de la Santé, Cotonou, Benin and the Ethical Committee of
the Institute of Tropical Medicine, Antwerp. Informed
consent was obtained from parents or guardians.
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Results
A total of 553 children, aged between six and 59 months,
were included in the study cohort. Among them, between
July 2003 and January 2005, 787 fever cases were identi-
fied: 567 had a P. falciparum infection, of whom 237 ful-
filled all inclusion criteria. These children were randomly
assigned to one of the study groups: 79 to CQ; 77 to SP
and 81 to the combination SP-AS (Figure 1). Most chil-
dren (90.7%) completed the 28-day follow up and were
included in the PP analysis. For the others, 11 parents/
guardians withdrew their consent, five children moved
out of the study area, and six were excluded because they
received another anti-malarial drug. All these children
were included in ITT analysis as failures and in the sur-
vival analysis as event-free for the time they participated.
The three treatment groups were comparable in terms of
demographic and clinical characteristics at baseline (Table
1).
Fever clearance was significantly more rapid in the SP-AS
than in the CQ or SP groups; by day 3 the prevalence of
fever was the following: SP-AS: 0/79 (0.0%), SP alone: 4/
67 (6.0%), CQ: 6/62 (9.7%) (p = 0.02). Parasite clearance
was also faster in the SP-AS than in the other two treat-
ment groups. By day 3, the percentage of children without
infection was 94.9% (75/79) in the SP-AS, 56.7% (38/67)
in the SP and 56.5% (35/62) in the CQ group (p < 0.001).
In the SP-AS group, no ETF was observed while there were
16 in the SP and 18 in the CQ group (Table 2). By day 14,
only one treatment failure (LPF) occurred in the SP-AS
group, while there were 8 (two LCF + six LPF) in the SP
group, and 21 (six LCF + 15 LPF) in the CQ group. Over-
all, TTF by day 14 (PP analysis) was 1.3% (1/77) for the
SP-AS group, 34.3% (24/70) for SP alone group and
54.9% (39/71) for the CQ group (p < 0.001).
By day 28, seven additional recurrent parasitaemia
occurred in the SP-AS group (one LCF and six LPF), seven
in the SP group (two LCF and five LPF), and 14 in the CQ
group (two LCF and 12 LPF). Thus, the failure rate (PCR
uncorrected) was 10.5% (8/76) for the SP-AS, 45.6% (31/
68) for the SP alone and 74.6% (53/71) for the CQ group.
After PCR correction, these rates were 5.3% (4/76), 44.1%
(30/68) and 71.8% (51/71), respectively (Table 2). The
odds of failure was significantly higher in the CQ than in
the SP alone group (OR = 3.2; 95% CI 1.5; 7.0) (p =
0.002); and for the latter it was significantly higher than
in the SP-AS group (OR = 14.2; 95% CI: 4.3; 58.5) (p <
0.001). Compared to SP-AS, the odds of failure for CQ
was 46 times higher (OR = 45.9; 95% CI: 14.0; 188.9) (p
< 0.0001).
Treatment failure rates estimated by Kaplan-Meier sur-
vival analysis (PCR-corrected) were similar (SP-AS 5.3%,
SP alone 42.0%, CQ 71.8%) to the PP analysis. Differ-
ences between study arms were highly significant (Log-
Rank p < 0,001) and the hazard of failure estimated by
Cox regression was 20 times higher with CQ compared to
SP-AS (HR = 20.7, 95% CI: 7.5; 57.5) (p < 0.001). For SP
alone versus SP-AS, the assumption of proportional haz-
ards was respected only after day 3: the hazard for treat-
ment failure was almost six times higher with SP
compared to SP-AS (HR = 5.7, 95% CI: 1.9; 18.2) (p =
0.002) (Figure 2).
Before treatment, no significant difference in gametocyte
prevalence was observed between groups although game-
tocyte carriages tended to be higher in the CQ group
(Table 1). Gametocyte carriage was significantly lower in
the SP-AS group compared to the two others, and by day
28 no patient in this group had gametocytes (Table 3).
Gametocyte carriage rate expressed as person-gametocyte-
weeks (PGW) was significantly lower in the SP-AS group
(16.7/1,000) than in the SP group (74.9/1,000) (p =
0.008). There was no difference in PGW when comparing
the SP-AS group to the CQ group (p = 0.33).
All children have been closely followed up by home visits
during 28 days (daily the first week, then weekly). In total,
28 serious adverse events were identified (three SP-AS, 15
CQ, 10 SP) (p = 0.15). No death was reported. No severe
malaria cases were observed in the SP-AS group while
there were two cases of convulsions in the other two
groups (one CQ and one SP) and five cases of severe anae-
mia (three CQ and two SP) (Table 4). Seven patients had
Trial profileFigure 1
Trial profile.  CQ = Chloroquine; *SP = Sulfadoxine-
Pyrimethamine;  AS = Artesunate.
567 cases of malaria
77 assigned to SP* 81 assigned to SP - AS°°
  76 completed Day 28
          follow up
79 assigned to CQ°
71 completed Day 28
       follow up
237 included in the trial
553 children in the cohort
        787 cases of fever
4 Consent withdrawals
1 Lost to follow-up
3 Another anti-malarial used
5 Consent withdrawals
2 Lost to follow-up
2 Another anti-malarial used
2 Consent withdrawals
2 Lost to follow-up
1 Another anti-malarial used
68 completed Day 28
        follow up
220 no malaria fevers
330 not eligible
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serious adverse events clearly related to acute respiratory
infection (three SP-AS, two CQ, two SP, p = 0.12) and one
patient in the SP group had pyomyositis.
Discussion
The combination SP-AS was safe, well-tolerated and sig-
nificantly more efficacious than the two other treatments.
Children treated with SP-AS had also a faster fever and
parasite clearance. At day 28, the PCR-corrected TTF for
Table 1: Baseline characteristics by treatment group
CQ (n = 79) SP (n = 77) SP-AS (n = 81)
Demographic characteristics
Sex ratio, Males:Females 36:43 46:31 43:38
Mean age in months [SD] 31.4 [13.8] 35.9 [16.9] 36.9 [16.3]
Mean weight in kg [SD] 13.4 [2.6] 13.7 [3.3] 14.3 [3.0]
Clinical characteristics
Days with fever before diagnosis, median [IQR]* 2 [1–3] 1 [0–3] 2 [1–3]
Mean body temperature, °C [SD] 38.3 [0.8] 38.3 [0.7] 38.2 [0.7]
Bed net use, n (%) 57 (72.1) 63 (81.1) 60 (74.0)
Parasite density (/μl)at Day 0, (geometric mean [range]) 16,323 [1,119; 198,107] 20,100 [1,192; 192,398] 20,286 [1,114; 198,609]
Gametocytaemia at day 0, n (%) 6 (7.6) 2 (2.6) 3 (3.7)
Packed cell volume, mean [range] 32.6 [22–43] 34.1 [26–40] 33.5 [23–43]
*IQR = Interquartile range
Table 2: Clinical and parasitological failure by day 14 and day 28
CQ SP SP – AS
DAY 14, n 71 70 77
ACPR 32 (45.1) 46 (65.7) 76 (98.7)
ETF, n (%) 18 (25.4) 16 (22.9) 0 (0.0)
LCF, n (%) 6 (8.5) 2 (2.9) 0 (0.0)
LPF, n (%) 15 (21.1) 6 (8.6) 1 (1.3)
TOTAL FAILURES
Per protocol, n (%) 39 (54.9) 24 (34.3) 1 (1.3)
Intention to Treat, n (%) 47/79 (59.5) 31/77 (40.3) 5/81 (6.2)
DAY 28 (PCR uncorrected), n 71 68 76
ACPR 18 (25.4) 37 (54.4) 68 (89.5)
ETF, n (%) 18 (25.4) 16 (23.5) 0 (0.0)
LCF, n (%) 8 (11.3) 4 (5.9) 1 (1.3)
LPF, n (%) 27 (38.0) 11 (16.2) 7 (9.2)
TOTAL FAILURES
Per protocol, n (%) 53 (74.6) 31 (45.6) 8 (10.5)
Intention to Treat, n (%) 61 (77.2) 40 (51.9) 13 (16.0)
DAY 28 (PCR corrected)
ACPR 20 (28.2) 38 (55.9) 72 (94.7)
ETF, n (%) 18 (25.4) 16 (23.5) 0 (0.0)
LCF, n (%) 8 (11.3) 4 (5.9) 1 (1.3)
LPF, n (%) 25 (35.2) 10 (14.7) 3 (3.9)
TOTAL FAILURES
New infections, n (%) 2 (14.3) 1 (14.3) 4 (57.1)
Per protocol, n (%) 51 (71.8) 30 (44.1) 4 (5.3)
Intention to Treat, n (%) 59 (74.7) 39 (50.6) 9 (11.1)
Kaplan Meier survival analysis (%) 71.8 42.0 5.3
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the SP-AS group was only 5.3%, an extremely low figure
compared to the other two treatments. These findings are
comparable to the 28-day PCR-corrected cure rates
recently reported from Ghana, (94.5%) [17] and eastern
Sudan (97.5%) [18]. The high treatment failure observed
in our study for both CQ and SP monotherapies suggests
a high prevalence of mutations linked to drug resistance
[19,21]. This may compromise the efficacy of ACT in
which the partner drug to the artemisinin-derivative
shares common resistance markers with either CQ or SP.
For example, when considering that there may be cross-
resistance between CQ and amodiaquine (AQ) [22-24],
the recently available fixed-dose combination AQ-artesu-
nate, one of the treatment included in the national anti-
malarial drug policy, may be less efficacious than
expected. It is often stated that in an ACT the partner drug
to the artemisinin derivative should have a good efficacy
and this because a 3-day treatment with artesunate is
insufficient to clear an infection. If the partner drug is not
effective, it is likely that a large number of infections,
incompletely treated, could re-appear during the patient
follow up. It is, therefore, surprising that in this study,
despite the high risk of treatment failure in the children
treated with SP alone, SP-AS had such a good efficacy.
Even the PCR-uncorrected results are extremely good as
only about 10% of the children in the SP-AS group expe-
rienced a failure or a recurrent infection, despite the high
transmission intensity, as compared to almost half of chil-
dren treated with SP alone. In Thailand, combining
artesunate with mefloquine considerably improved the
efficacy of treatment, despite the high resistance to meflo-
quine itself [25]. However, the intensity of malaria trans-
mission in Benin is much higher than in Thailand and
new infections are more likely to occur shortly after treat-
ment. However, a longer follow up may have detected
more cases of recurrent parasitaemia or even recrudes-
cence [26]. It is also possible that the high bed net use
among the study children may have limited their risk of
new infections.
As expected, gametocyte carriage in children treated with
SP-AS was much lower than in the other treatment groups.
A decrease in malaria transmission after the introduction
of ACT has already been reported in Thailand and it has
been suggested that this was linked to the lower gameto-
cyte production in patients treated with ACT [25]. How-
ever, considering that malaria transmission in Africa,
more specifically in the coastal lagoon area of Cotonou, is
much higher than in south-east Asia, it is unclear whether
the introduction of ACT will have a major impact on
Table 3: Gametocyte carriage by treatment group
CQ SP SP-AS p value
Gametocyte 
prevalence, n (%)
Day 0 79 (7.6) 77(2.6) 81(3.7) 0.31
Day 7 53 (5.7) 56(16.1) 77(3.9) 0.03
Day 14 45(6.7) 47(10.6) 77(2.6) 0.18
Day 28 25(12.0) 40(10) 72(0.0) 0.02
Gametocyte incidence, 
n (%)
Day 7 49(6.1) 55(16.4) 75(2.7) 0.01
Day 14 41(4.9) 47(10.6) 75(2.7) 0.17
Day 28 24(12.5) 40(9.8) 70(0.0) 0.02
Person-gametocyte-
weeks (/1000 person-
weeks)
6/154 (39.0) 14/187 (74.9) 5/301 (16.7) 0.02†
†Kruskal-Wallis p-value.
Kaplan Meier survival curves (PCR Adjusted) by treatment groupFig re 2
Kaplan Meier survival curves (PCR Adjusted) by treatment 
group.
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transmission. Nevertheless, anecdotic reports of a lower-
than-expected number of malaria patients at health facili-
ties in several African countries have been produced [27].
It is unclear whether this is a true phenomenon and, if yes,
this is due to the introduction of ACT or also to other
interventions such as insecticide-treated bed nets.
Conclusion
Benin recently chose artemether-lumefantrine and amo-
diaquine-artesunate as recommended treatments for
uncomplicated malaria. This decision was taken in 2004
but it is unfortunate to notice that these ACT are not avail-
able yet at peripheral health facilities. Other African coun-
tries such as Burkina Faso are in a similar situation, i.e. the
national drug policy has been changed but not imple-
mented yet (Tinto Halidou., personal communication).
In Benin, considering that SP and AS are easily available
and their combination has an acceptable efficacy, SP-AS
may be used whenever the recommended standard treat-
ments are hopefully temporarily unavailable. However,
because SP is also used in pregnant women as intermittent
preventive treatment (IPTp), its combination with AS
should not be widely employed in malaria patients as this
may compromise the efficacy of IPTp.
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